Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 210

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 210
---
ment Proposal
requires the affirmative vote, in person or by proxy, of the majority of the voting power of the shares present in person or represented by proxy at the Special Meeting and entitled to vote on the subject matter. You may vote “FOR,”
“AGAINST” or “ABSTAIN” such matter. Broker non-votes, if any, will not be counted as entitled to vote on the subject matter for this proposal and accordingly, will have no effect on the outcome of the Adjournment Proposal, and
abstentions will be counted in the same manner as votes “AGAINST” the Adjournment Proposal.

THE AADI BOARD OF DIRECTORS RECOMMENDS A VOTE “FOR” THE ADJOURNMENT PROPOSAL

- 146 -

EXECUTIVE OFFICERS Our executive officers as of January 30, 2025 and their biographical information are set forth below:

| Name                |     | Age |     | Position(s)                                   |
| David Lennon, Ph.D. |     |  55 |     | Director; President & Chief Executive Officer |
| Scott Giacobello    |     |  54 |     | Chief Financial Officer and Treasurer         |
| Bryan Ball          |     |  55 |     | Chief Technical Operations Officer            |

David Lennon, Ph.D. Please see the biographical information provided below in the section entitled “ Board of Directors.” Scott Giacobellohas served as Chief Financial Officer since November 2021 and was our interim Chief Executive Officer and President from March 2023 to October 2023. Prior to joining Aadi, Mr. Giacobello served as the Chief Financial Officer of GW Pharmaceuticals plc, a global pharmaceuticals company, from March 2017 until its acquisition by Jazz Pharmaceuticals plc in May 2021. Prior to joining GW Pharmaceuticals, Mr. Giacobello served as Chief Financial Officer of Chase Pharmaceuticals Corporation, a clinical stage biopharmaceutical company focused on the development and commercialization of improved treatments for neurodegenerative disorders, until it was acquired by Allergan plc (now a wholly owned subsidiary of AbbVie Inc.) in 2016. From 2008 through 2015, Mr. Giacobello held senior level finance positions at Allergan including Vice President of Finance for Global Research & Development, Vice President of Corporate Finance and Vice President of Internal Audit & Compliance. Mr. Giacobello’s previous experience includes financial positions at the Black & Decker Corporation and Ernst &